Ajanta Pharma Intrinsic Value
AJANTPHARM Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1833.04 | ₹1466.43 - ₹2199.65 | -35.6% | EPS: ₹83.32, Sector P/E: 22x |
| Book Value Method | asset | ₹3032.00 | ₹2728.80 - ₹3335.20 | +6.6% | Book Value/Share: ₹1516.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4521.60 | ₹4069.44 - ₹4973.76 | +59.0% | Revenue/Share: ₹2260.80, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹5688.80 | ₹5119.92 - ₹6257.68 | +100.0% | EBITDA: ₹1548.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹6286.37 | ₹5029.10 - ₹7543.64 | +121.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹853.32 | ₹767.99 - ₹938.65 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1287.29 | ₹1158.56 - ₹1416.02 | -54.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹5688.80 | ₹5119.92 - ₹6257.68 | +100.0% | ROE: 27.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1685.84 | ₹1517.26 - ₹1854.42 | -40.7% | EPS: ₹83.32, BVPS: ₹1516.00 |
Want to compare with current market value? Check AJANTPHARM share price latest .
Valuation Comparison Chart
AJANTPHARM Intrinsic Value Analysis
What is the intrinsic value of AJANTPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Ajanta Pharma (AJANTPHARM) is ₹3032.00 (median value). With the current market price of ₹2844.40, this represents a +6.6% variance from our estimated fair value.
The valuation range spans from ₹853.32 to ₹6286.37, indicating ₹853.32 - ₹6286.37.
Is AJANTPHARM undervalued or overvalued?
Based on our multi-method analysis, Ajanta Pharma (AJANTPHARM) appears to be trading near calculated value by approximately 6.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.41 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.32 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 27.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 24.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.13x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Ajanta Pharma
Additional stock information and data for AJANTPHARM
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,157 Cr | ₹969 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹785 Cr | ₹785 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹792 Cr | ₹512 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹562 Cr | ₹525 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹576 Cr | ₹435 Cr | Positive Free Cash Flow | 8/10 |